Therapy Areas: Inflammatory Diseases
Eilean Therapeutics presents TE205 in vivo data at 4th International Conference on Microbiology and Immunology
5 November 2025 - Eilean Therapeutics LLC, a US-based biopharmaceutical company, on Tuesday reported in vivo data for its first-in-class MALT1 degrader, TE205, as a disease-modifying therapy for ulcer...
Arctic Bioscience reports significant anti-inflammatory effects from psoriasis drug candidate HRO350 in phase 2b trial
4 November 2025 - Biotech company Arctic Bioscience AS (Euronext Growth Oslo:ABS) reported on Tuesday that analysis of blood samples from its phase 2b HeROPA study showed statistically significant eff...
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
29 October 2025 - Animal health business Zoetis Inc (NYSE: ZTS) announced on Wednesday that the European Commission has granted marketing authorization for Portela (relfovetmab), the first monoclonal ...
Johnson & Johnson reports durable two-year remission data for TREMFYA in Crohn's disease
27 October 2025 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Monday announced new 96-week data from the Phase 3 GRAVITI, GALAXI 2, and GALAXI 3 studies, confirming the long-term effica...
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
22 October 2025 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Wednesday that it has signed a 12-month contract with one of the world's largest Clinical Research Organisations (...
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
21 October 2025 - The Lupus Foundation of America Inc reported on Monday that the US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab), developed by biotechnology company Genentech...